Search results
Breast Cancer Patients With VUS Generally Not Overtreated, Real-World Data Analysis Suggests
GenomeWeb News· 4 days agoDespite concerns that breast cancer patients receive unnecessary surgery, surveillance, and therapy based on variants of uncertain significance (VUS), researchers at the American Society of ...
Case Study: Patient with Rare Breast Cancer Has Surprising Response to NAC
MedPage Today· 3 days ago"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey ...
ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC
Pharmaceutical Technology via Yahoo Finance· 7 days agoAt the ongoing American Society of Clinical Oncology (ASCO) Congress 2024, investigators revealed...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoSunvozertinib's Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations PR Newswire SHANGHAI, June 2, 2024 The global pivotal WU-KONG1B study investigating sunvozertinib achieved
OPINION: Russia is flooding Europe with disinformation. The U.S. elections are next.
Anchorage Daily News· 6 days agoIn 2022, European monitors who track Russian disinformation spotted an ambitious online influence...
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in...
Benzinga· 6 days agoSUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related
BriaCell Presents Clinical Efficacy Data at ASCO 2024
Digital Journal· 5 days agoBriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug ...
Natural History of Nonmetastatic Prostate Cancer Managed With Watchful Waiting
Journal of the American Medical Association· 4 days agoThis cohort study examines whether a watchful waiting treatment strategy is associated with adverse outcomes in men with nonmetastatic prostate cancer and a life expectancy of less than 10 years in Sweden.
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC...
WLNS Lansing· 7 days agoGenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in...
Merck, Moderna Drug Combo Shows Improved Survival in Skin Cancer Trial
Morningstar· 5 days agoModerna and Merck said they saw positive results from a Phase 2b study evaluating mRNA-4157 in combination with Keytruda in patients with high-risk skin cancer that was surgically removed. With ...
